VivoSeq
Oncology

Prostatic Neoplasms, Castration-Resistant

8

Pipeline Programs↗

5

Active Trials↗

7

Companies Involved↗

Prostatic Neoplasms, Castration-Resistant is an early-stage landscape with 8 programs across 7 companies. The most active players are Aragon Pharmaceuticals, Inc., Eli Lilly, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

15/100

Mech. Concentration

20/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Aragon Pharmaceuticals, Inc.

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1Takeda logo

Takeda

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

5

clinical trials

Not yet recruiting3 · 60%
Active, not recruiting2 · 40%

Clinical Trials

Trial Activity

Real World Clinical Effectiveness of [177Lu]Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients: A Non-Interventional Study
Not yet recruiting·Novartis logoNovartis·N/A·NCT07697989·1,085 enrolled
A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT03431350·136 enrolled
Drug-drug Interaction Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Subjects With Castration-Resistant Prostate Cancer
Active, not recruiting·AAragon Pharmaceuticals, Inc.·Phase 1·NCT02592317·23 enrolled
Real-World Characteristics, Treatment Patterns, and Outcomes Among Adults With mCRPC Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Not yet recruiting·Novartis logoNovartis·N/A·NCT07677267·1,067 enrolled
Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform
Not yet recruiting·Novartis logoNovartis·N/A·NCT07677254·17,111 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)